Aclaris Therapeutics, INC DEF 14A proxy statements

Aclaris Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, detailing proposals for director elections, executive compensation, and auditor ratification.

Aclaris Therapeutics is holding its 2025 Annual Meeting on June 5, 2025, seeking stockholder votes on director elections, executive compensation, an increase in authorized common stock, approval of an equity incentive plan, and ratification of the company's independent auditor.

Aclaris Therapeutics is asking stockholders to vote on key proposals including increasing authorized common stock and approving a new equity incentive plan at the upcoming annual meeting.

Aclaris Therapeutics, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 6, 2024, with proxy materials now available for review and voting.

Aclaris Therapeutics' upcoming annual meeting on June 6, 2024, will address director elections, executive compensation, and the ratification of PricewaterhouseCoopers LLP as the company's independent auditor.